The results of this study suggest that TCcp (250 and 500 mg/kg) has a promising effect on the GLU-induced catabolic muscular atrophy, through antioxidative and anti-inflammatory functions, mediated by the modulation of genes involved in the protein degradation (MuRF1, atrogin-1, SIRT1, and myostatin) and synthesis (PI3K, Akt1, TRPV4, and A1R) of muscle. The gene discussed is FBXO32; the disease is muscular atrophy.